Abstract: A magnetic geared electrical machine includes: a stator; a magnetic pole piece rotor including a plurality of magnetic pole pieces disposed radially inward of the stator; an inner rotor including a plurality of rotor magnets, disposed radially inward of the plurality of magnetic pole pieces, and configured to rotate at a higher speed than the magnetic pole piece rotor; and a fan for cooling at least one of the stator, the magnetic pole piece rotor, or the inner rotor. The magnetic pole piece rotor further includes a power transmission shaft disposed on one side in an axial direction relative to the plurality of magnetic pole pieces, and configured to transmit rotational power to and from an external device. The fan is disposed in the inner rotor on an opposite side to the power transmission shaft with the rotor magnet therebetween in the axial direction.

Abstract: A heat insulator is disclosed which simplifies processes of measures for preventing contamination of a surrounding caused by falling off of a silica aerogel in a silica-aerogel support heat insulator. In the silica-aerogel support heat insulator, a support layer whose melting point is lower than a melting point of a fiber supporting the silica aerogel is used, and by performing thermal-pressure bonding at a temperature lower than the melting point of the fiber but higher than the melting point of the support layer to cause the support layer to enter the fiber to combine the support layer and the fiber. Thus, processes of measures for preventing contamination of a surrounding caused by falling off of the silica aerogel can be simplified, and use in a large size and/or in a complicated shape is made possible.

Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.

Abstract: An information transmission apparatus 2 makes transmission objective data redundant using a predetermined method, divides the redundant data into N (N?2) data elements, the transmission objective data being reproducible on the basis of any arbitrary combination of m (m<N) or more data elements, and sequentially transmits short-range communication signals respectively including the N data elements obtained by the division. A terminal apparatus 3 which receives the data elements tries to reproduce the data using the received data elements, and transmits short-range communication signals including the received data elements.

Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.

Abstract: An information transmission apparatus 2 makes transmission objective data redundant using a predetermined method, divides the redundant data into N (N?2) data elements, the transmission objective data being reproducible on the basis of any arbitrary combination of m (m<N) or more data elements, and sequentially transmits short-range communication signals respectively including the N data elements obtained by the division. A terminal apparatus 3 which receives the data elements tries to reproduce the data using the received data elements, and transmits short-range communication signals including the received data elements.

Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.

Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.

Abstract: A method of preventing a lowering of concentration of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? isopropyl ester, the prostaglandin derivative being contained in an ophthalmic solution as an active ingredient. The method including (i) adding to the ophthalmic solution a nonionic surfactant to inhibit the prostaglandin derivative from being adsorbed to a container which contains the ophthalmic solution, the container being made of a resin and (ii) adding to the ophthalmic solution an antioxidant to inhibit decomposition of the prostaglandin derivative.

Abstract: An object of the present invention is to formulate prostaglandin derivatives which are hardly soluble in water and liable to be adsorbed to a resinous container and prostaglandin derivatives which are liable to decompose when dissolved in water in ophthalmic solutions. Solubility of the prostaglandin derivatives in water is improved and the adsorption thereof to the resinous container can be remarkably inhibited by adding a nonionic surfactant such as polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 to the ophthalmic solutions. The decomposition of the prostaglandin derivatives can be remarkably inhibited by adding an antioxidant such as disodium ethylenediaminetetraacetate or dibutylhydroxytoluene.